Bristol Myers Squibb shared promising data on CC-97540, a new CAR T Cell Therapy for autoimmune diseases, at ACR 2024. Manufactured using NEX-TTM process, it showed positive safety and efficacy results, demonstrating potential as a key growth driver for the company.